Suppr超能文献

监测在SMART研究(西班牙,2016年和2017年)期间分离出的、与腹腔内感染及泌尿道感染相关的革兰氏阴性菌的药敏情况。

Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017).

作者信息

Cantón R, Loza E, Aznar J, Castillo F J, Cercenado E, Fraile-Ribot P A, González-Romo F, López-Hontangas J L, Rodríguez-Lozano J, Suárez-Barrenechea A I, Tubau F, Díaz-Regañón J, López-Mendoza D

机构信息

Rafael Cantón. Servicio de Microbiología. Hospital Universitario Ramón y Cajal. Carretera de Colmenar Km 9,1. 28034 Madrid. Spain.

出版信息

Rev Esp Quimioter. 2019 Apr;32(2):145-155. Epub 2019 Feb 13.

Abstract

OBJECTIVE

Continuous antimicrobial resistance surveillance is recommended by Public Health authorities. We up-dated data from the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain.

METHODS

The antimicrobial susceptibility data and extended-spectrum beta-lactamase (ESBL) production in isolates recovered from intra-abdominal (IAI) (n=1,429) and urinary tract (UTI) (n=937) infections during the 2016- 2017 SMART study in 10 Spanish hospitals were analysed.

RESULTS

Escherichia coli was the most frequently microorganism isolated (48.3% and 53.7%) followed by Klebsiella spp. (11.5% and 21.9%) in IAIs and UTIs, respectively. Figures for Pseudomonas aeruginosa were 9.0% and 6.1%, being more frequently recovered from patients with nosocomial infections. Overall, 9.9% (IAI) and 14.0% (UTI) of E. coli, Klebsiella spp. and Proteus mirabilis isolates were ESBL-producers, being Klebsiella pneumoniae (34.5%) from UTI of nosocomial origin the most frequent. ESBL-producers were higher in patients >60 years in both IAIs and UTIs. As in previous years, amikacin (96.3%-100% susceptibility), ertapenem (84.2%-100%) and imipenem (70.3%- 100%) were the most active antimicrobials tested among Enterobacterales species. The activity of amoxicillin-clavulanic, piperacillin-tazobactam, and ciprofloxacin susceptibility was lower, particularly among ESBL-producers. Ertapenem susceptibility (88.9%-100%) was retained in ESBL-E. coli isolates that were resistant to these antimicrobials but decreased (28.6%-100%) in similar isolates of K. pneumoniae.

CONCLUSIONS

Continuous antimicrobial resistance surveillance from the SMART study reveals overall maintenance of ESBL-producers in Spain, although with higher presence in isolates from UTIs than from IAIs. Moreover, ertapenem activity was high in E. coli irrespective of ESBL production but decreased in K. pneumoniae, particularly among ESBL-producers.

摘要

目的

公共卫生当局建议持续进行抗菌药物耐药性监测。我们更新了西班牙SMART(监测抗菌药物耐药性趋势研究)监测研究的数据。

方法

分析了2016 - 2017年在西班牙10家医院进行的SMART研究中,从腹腔内感染(IAI)(n = 1429)和尿路感染(UTI)(n = 937)中分离出的菌株的抗菌药物敏感性数据和超广谱β-内酰胺酶(ESBL)产生情况。

结果

大肠埃希菌是最常分离出的微生物(分别占IAI和UTI的48.3%和53.7%),其次是克雷伯菌属(分别占IAI和UTI的11.5%和21.9%)。铜绿假单胞菌在IAI和UTI中的占比分别为9.0%和6.1%,在医院感染患者中更常分离到。总体而言,大肠埃希菌、克雷伯菌属和奇异变形杆菌分离株中,9.9%(IAI)和14.0%(UTI)为ESBL产生菌,医院源性UTI中的肺炎克雷伯菌(34.5%)是最常见的ESBL产生菌。在IAI和UTI中,60岁以上患者的ESBL产生菌比例更高。与前几年一样,在肠杆菌科细菌中,阿米卡星(敏感性96.3% - 100%)、厄他培南(84.2% - 100%)和亚胺培南(70.3% - 100%)是测试中活性最高的抗菌药物。阿莫西林-克拉维酸、哌拉西林-他唑巴坦和环丙沙星的敏感性较低,尤其是在ESBL产生菌中。对这些抗菌药物耐药的ESBL-大肠埃希菌分离株对厄他培南仍有敏感性(88.9% - 100%),但肺炎克雷伯菌的类似分离株中敏感性降低(28.6% - 100%)。

结论

SMART研究的持续抗菌药物耐药性监测显示,西班牙ESBL产生菌总体维持稳定,尽管UTI分离株中的比例高于IAI分离株。此外,厄他培南对大肠埃希菌的活性较高,与ESBL产生情况无关,但在肺炎克雷伯菌中活性降低,尤其是在ESBL产生菌中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b97/6441989/7df5e499e05b/revespquimioter-32-145-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验